Güttner J
Agents Actions. 1979 Dec;9(5-6):527-33. doi: 10.1007/BF01968123.
Beta-[1-Phenyl-5-bis(beta-chloroethyl)-amino-benzimidazolyl-(2)]-DL-alanin (ZIMET 3164), a highly immunosuppressive but moderately cytostatic agent, was found to be able to prevent the progression of spontaneous murine immune complex nephritis in a dose-dependent fashion. For experiments, BCG-stimulated conventional female (NMRI X NZB)F1 mice suffering from rapidly progressive nephritis, BCG-stimulated and unilaterally nephrectomized (NMRI X NZB)F1 females, and (AB/Jena X NZB)F1 females characterized by a prolonged course of the disease were used. The beneficial effect was quantified by fluorescence photometry and histometry, and semiquantitatively detected by estimation of the extent of damage of individual glomerular structures when histometric methods were unsuited. Treatment of young adult animals characterized by slight to moderate glomerular lesions was more effective than of older ones with advanced nephritis. At equi-immunosuppressive dose levels ZIMET 3164 was about twice as effective as the reference substance cyclophosphamide.
β-[1-苯基-5-双（β-氯乙基）-氨基-苯并咪唑基-（2）]-DL-丙氨酸（ZIMET 3164）是一种高度免疫抑制但细胞生长抑制作用中等的药物，发现它能够以剂量依赖的方式阻止自发性小鼠免疫复合物性肾炎的进展。实验使用了患有快速进行性肾炎的卡介苗刺激的常规雌性（NMRI×NZB）F1小鼠、卡介苗刺激并单侧肾切除的（NMRI×NZB）F1雌性小鼠以及疾病病程延长的（AB/Jena×NZB）F1雌性小鼠。通过荧光光度法和组织测量法定量有益效果，当组织测量方法不适用时通过估计单个肾小球结构的损伤程度进行半定量检测。治疗以轻度至中度肾小球病变为特征的年轻成年动物比治疗患有晚期肾炎的老年动物更有效。在同等免疫抑制剂量水平下，ZIMET 3164的效果约为参考物质环磷酰胺的两倍。
